RecruitingPhase 1ketamine

Pilot Study of RR-HNK in OCD

Sponsored by Carolyn Rodriguez

NCT ID
NCT06575075
Target Enrollment
45 participants
Start Date
2025-11-01
Est. Completion
2029-11-30

About This Study

The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.

Conditions Studied

Obsessive-Compulsive Disorder

Interventions

  • RR-HNK/Hydroxynorketamine
  • Placebo

Eligibility

Age:18 Years - 65 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* Ages 18-65
* Meet the criteria for OCD diagnosis
* Failed at least 1 prior trial of standard first-line OCD treatment (e.g. SRI/CBT) or or had refused these treatments for individual reasons
* Agree to the following lifestyle modifications: comply with requirements for fasting prior to --the infusion session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures.
* Able to provide informed consent

Exclusion Criteria:

* Allergy or hypersensitivity to ketamine
* Any current or past medical/psychiatric condition that makes participation unsafe in the opinion of the investigator or study physician
* Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control
* Lifetime history of deep brain stimulation

Study Locations (1)

Stanford University School of Medicine
Palo Alto, California, United States

Interested in this trial?

Contact the study team to learn more about eligibility and enrollment.

View on ClinicalTrials.gov
Data Source
ClinicalTrials.gov

Last updated from source

Pilot Study of RR-HNK in OCD | Huxley